Technology area: Biotechnology & Pharmaceuticals
16 pending office actions • 7 art units • 13 examiners • 0 of 16 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Myriad Genetics Inc. has 17 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 15 distinct examiners across 7 distinct art units, showing broad examiner coverage with some concentration in the technical groupings.
WHALEY, PABLO S is the busiest examiner, with 2 pending matters. Those matters may support comparison of examiner treatment, but the remaining assignments require separate review and response planning.
Counsel can use the art-unit structure to identify recurring issues involving biotechnology and pharmaceutical claim scope. A coordinated review of written description, prior art, and amendment positions may improve consistency without replacing matter-specific prosecution analysis.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (6%) |
| §101 + other | 10 (62%) |
| §103 only | 1 (6%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 1 (6%) |
| No statute on record | 2 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHALEY, PABLO S | 3 | 25.0% | +21.3% |
| DAUNER, JOSEPH G | 2 | 57.0% | +35.3% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +47.5% |
| SMITH, EMILIE ALINE | 1 | 49.4% | +35.4% |
| HOPPE, EMMA RUTH | 1 | 40.0% | +58.3% |
| HORLICK, KENNETH R | 1 | 79.0% | +15.3% |
| LU, FRANK WEI MIN | 1 | 62.7% | +67.9% |
| HANEY, AMANDA MARIE | 1 | 36.5% | +45.0% |
| ZEMAN, MARY K | 1 | 58.9% | +34.2% |
| PHAM, KHAI QUYNH TIEN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19088442 | METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY | WHALEY, PABLO S | 35d overdue |
| 19088496 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY | SITTON, JEHANNE SOUAYA | 4d overdue |
| 17353279 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY | HANEY, AMANDA MARIE | 4d overdue |
| 18646644 | ELECTRONIC VARIANT CLASSIFICATION | WHALEY, PABLO S | — |
| 18277554 | GLOBAL POLYGENIC RISK ASSESSMENT FOR BREAST CANCER | DAUNER, JOSEPH G | — |
| 17920012 | COMPREHENSIVE POLYGENIC RISK PREDICTION FOR BREAST CANCER | SMITH, EMILIE ALINE | — |
| 18076279 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY IN BREAST CANCER SUBTYPES | HOPPE, EMMA RUTH | — |
| 17678357 | GENE SIGNATURES FOR CANCER PROGNOSIS | HORLICK, KENNETH R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19088442 | METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY | WHALEY, PABLO S | 35d overdue |
| 19088496 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY | SITTON, JEHANNE SOUAYA | 4d overdue |
| 17353279 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY | HANEY, AMANDA MARIE | 4d overdue |
| 18646644 | ELECTRONIC VARIANT CLASSIFICATION | WHALEY, PABLO S | — |
| 18277554 | GLOBAL POLYGENIC RISK ASSESSMENT FOR BREAST CANCER | DAUNER, JOSEPH G | — |
| 17920012 | COMPREHENSIVE POLYGENIC RISK PREDICTION FOR BREAST CANCER | SMITH, EMILIE ALINE | — |
| 18076279 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY IN BREAST CANCER SUBTYPES | HOPPE, EMMA RUTH | — |
| 17678357 | GENE SIGNATURES FOR CANCER PROGNOSIS | HORLICK, KENNETH R | — |
| Art Unit | Apps |
|---|---|
| 1682 | 5 |
| 3619 | 3 |
| 1686 | 2 |
| 1683 | 2 |
| 1687 | 2 |
| 1681 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19088496 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY | SITTON, JEHANNE SOUAYA | 1682 | §101§103Other | Non-Final OA | 4d overdue | Pending | Mar 24, 2025 |
| 19088442 | METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY | WHALEY, PABLO S | 3619 | §103§112Other | Non-Final OA | 35d overdue | Pending | Mar 24, 2025 |
| 18646644 | ELECTRONIC VARIANT CLASSIFICATION | WHALEY, PABLO S | 3619 | §101§112 | Final Rejection | — | Pending | Apr 25, 2024 |
| 18277554 | GLOBAL POLYGENIC RISK ASSESSMENT FOR BREAST CANCER | DAUNER, JOSEPH G | 1682 | §101§102§112 | Final Rejection | — | Pending | Aug 16, 2023 |
| 17920012 | COMPREHENSIVE POLYGENIC RISK PREDICTION FOR BREAST CANCER | SMITH, EMILIE ALINE | 1686 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 24, 2023 |
| 18076279 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY IN BREAST CANCER SUBTYPES | HOPPE, EMMA RUTH | 1683 | §101§103Other | Non-Final OA | — | Pending | Dec 06, 2022 |
| 17678357 | GENE SIGNATURES FOR CANCER PROGNOSIS | HORLICK, KENNETH R | 1681 | §101 | Non-Final OA | — | Pending | Feb 23, 2022 |
| 17545611 | METHODS AND MATERIALS FOR ASSESSING ALLELIC IMBALANCE | LU, FRANK WEI MIN | 1683 | Other | Final Rejection | — | Pending | Dec 08, 2021 |
| 17499284 | METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY | WHALEY, PABLO S | 3619 | §101§112Other | Non-Final OA | — | Pending | Oct 12, 2021 |
| 17353279 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY | HANEY, AMANDA MARIE | 1682 | §101§103§112DP | Non-Final OA | 4d overdue | Pending | Jun 21, 2021 |
| 17096755 | GENE SIGNATURES FOR CANCER PROGNOSIS | DAUNER, JOSEPH G | 1682 | Other | Final Rejection | — | Pending | Nov 12, 2020 |
| 18020416 | BAYESIAN SEX CALLER | ZEMAN, MARY K | 1686 | §101§103§112 | Non-Final OA | — | Pending | Feb 08, 2023 |
| 17926566 | NUCLEIC ACID SAMPLE ENRICHMENT AND SCREENING METHODS | PHAM, KHAI QUYNH TIEN | 1684 | §103 | Non-Final OA | — | Pending | Nov 18, 2022 |
| 17716381 | ENRICHMENT OF CELL-FREE DNA FROM A BIOLOGICAL SAMPLE | BUCHANAN, BAILEY CHEYENNE | 1682 | §102§103DP | Non-Final OA | — | Pending | Apr 08, 2022 |
| 17630385 | METHOD FOR DETECTING GENETIC VARIATION IN HIGHLY HOMOLOGOUS SEQUENCES BY INDEPENDENT ALIGNMENT AND PAIRING OF SEQUENCE READS | ANDERSON-FEARS, KEENAN NEIL | 1687 | §101§103DP | Non-Final OA | — | Pending | Jan 26, 2022 |
| 17111272 | COPY NUMBER VARIANT CALLER | PULLIAM, JOSEPH CONSTANTINE | 1687 | §101§103§112DP | Non-Final OA | — | Pending | Dec 03, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMyriad Genetics Inc. has 16 pending office actions as of October 2026, spread across 7 art units and 13 examiners.
Pablo S Whaley has the most, with 3 of Myriad Genetics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
